

**British Association of Dermatologists  
Response to NICE Final appraisal determination  
On the Single Technology Appraisal  
Pembrolizumab for adjuvant treatment of melanoma with high risk of  
recurrence [ID1266]**

**British Association of Dermatologists  
Therapy & Guidelines**

On behalf of the British Association of Dermatologists, thank you for the opportunity to comment on the Final appraisal determination.  
The British Association of Dermatologists have no comments.

**Prof Nick Levell  
Chair, Therapy & Guidelines sub-committee**